Kyverna Therapeutics (KYTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors, Ian Clark and Christi Shaw, to serve until the 2029 annual meeting.
Ratification of BDO USA, P.C. as independent auditor for the year ending December 31, 2026.
Proxies may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Audit Committee selected BDO USA, P.C. as the independent registered public accounting firm for 2026.
Shareholders are asked to ratify this appointment at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kyverna Therapeutics
- Miv-cel achieved robust, durable efficacy and drug-free remission in SPS and gMG, supporting launch.KYTX
Status update22 Apr 2026 - Proposals include director elections and auditor ratification, with strong governance and ESG oversight.KYTX
Proxy filing13 Apr 2026 - Miv-cel demonstrates transformative efficacy in autoimmune diseases, targeting SPS and gMG first.KYTX
Corporate presentation26 Mar 2026 - Shelf registration enables up to $300M in offerings, targeting autoimmune therapy growth.KYTX
Registration filing26 Mar 2026 - BLA filing for first-in-class CAR T in SPS expected 1H 2026, with $279M cash runway into 2028.KYTX
Q4 202526 Mar 2026 - Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year.KYTX
Leerink Global Healthcare Conference 20269 Mar 2026 - Transformative CAR-T efficacy in SPS and MG drives first-to-market plans and strong financial outlook.KYTX
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Miv-cel achieved breakthrough efficacy in SPS and MG, with launch readiness and strong financials.KYTX
Investor presentation12 Jan 2026 - Pivotal CAR-T trials in autoimmune diseases show durable efficacy, safety, and broad expansion plans.KYTX
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026